Barcelona Alzheimer Treatment & Research Center

Posts Tagged 2014

Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration.

Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Van der Zee J, Van Langenhove T, Kovacs GG, Dillen L, Deschamps W, Engelborghs S, Matěj R, Vandenbulcke M, Sieben A, Dermaut B, Smets K, Van Damme P, Merlin C, Laureys A, Van Den Broeck M, Mattheijssens M,






Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders.

Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Gelpi E, Navarro-Otano J, Tolosa E, Gaig C, Compta Y, Rey MJ, Martí MJ, Hernández I, Valldeoriola F, Reñé R, Ribalta T. Mov Disord.2014 Jul;29(8):1010-8. doi: 10.1002/mds.25776. Epub 2014 Jan 2.






Cognitive, genetic, and brain perfusion factors associated with four year incidence of Alzheimer’s disease from mild cognitive impairment.

Cognitive, genetic, and brain perfusion factors associated with four year incidence of Alzheimer’s disease from mild cognitive impairment. Alegret M, Cuberas-Borrós G, Espinosa A, Valero S, Hernández I, Ruíz A, Becker JT, Rosende-Roca M, Mauleón A, Sotolongo O, Castell-Conesa J, Roca I, Tárraga L, Boada M. J Alzheimers Dis. 2014;41(3):739-48. PDF






Effects of Gingko biloba supplementation in Alzheimer’s disease patients receiving cholinesterase inhibitors: data from the ICTUS study.

Effects of Gingko biloba supplementation in Alzheimer’s disease patients receiving cholinesterase inhibitors: data from the ICTUS study. Canevelli M, Adali N, Kelaiditi E, Cantet C, Ousset PJ, Cesari M;ICTUS/DSA Group. Phytomedicine. 2014 May 15;21(6):888-92. PDF






A 2-year prospective cohort study of antidementia drug non-persistency in mild-to-moderate Alzheimer’s disease in Europe : predictors of discontinuation and switch in the ICTUS study.

A 2-year prospective cohort study of antidementia drug non-persistency in mild-to-moderate Alzheimer’s disease in Europe : predictors of discontinuation and switch in the ICTUS study. Gardette V, Lapeyre-Mestre M, Piau A, Gallini A, Cantet C, Montastruc JL, Vellas B, Andrieu S; ICTUS Group. CNS Drugs. 2014 Feb;28(2):157-70.






Utilidad del subtest Semejanzas de la Escala de Inteligencia de Wechsler para Adultos-III y su relación con la conciencia de déficit en la evaluación forense del deterioro cognitivo.

Utilidad del subtest Semejanzas de la Escala de Inteligencia de Wechsler para Adultos-III y su relación con la conciencia de déficit en la evaluación forense del deterioro cognitivo. Espinosa A, Alegret A, Ibarria M, Ortega G, Cañabate P, Boada M. Revista Española de Medicina Legal. 10.1016/j.reml.2014.03.001 PDF






A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Tolosa E, Litvan I, Höglinger GU, Burn D, Lees A, Andrés MV, Gómez-Carrillo B, León T, Del Ser T; TAUROS Investigators. Mov Disord. 2014 Apr;29(4):470-8. doi: 10.1002/mds.25824.






Frontotemporal dementia and its subtypes: a genome-wide association study.

Frontotemporal dementia and its subtypes: a genome-wide association study. Ferrari R, Hernandez DG, Nalls MA, Rohrer JD, Ramasamy A, Kwok JB, Dobson-Stone C, Brooks WS, Schofield PR, Halliday GM, Hodges JR, Piguet O, Bartley L, Thompson E, Haan E, Hernández I, Ruiz A, Boada M, Borroni B, Padovani A, Cruchaga C,






Gene-wide analysis detects two new susceptibility genes for Alzheimer’s disease.

Gene-wide analysis detects two new susceptibility genes for Alzheimer’s disease. Escott-Price V, Bellenguez C, Wang LS, Choi SH, Harold D, Jones L, Holmans P, Gerrish A, Vedernikov A, Richards A, DeStefano AL, Lambert JC, Ibrahim-Verbaas CA, Naj AC, Sims R, Jun G, Bis JC, Beecham GW, Grenier-Boley B,






Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial.

Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Höglinger GU1, Huppertz HJ, Wagenpfeil S, Andrés MV, Belloch V, León T, Del Ser T; TAUROS MRI Investigators. Mov Disord. 2014 Apr;29(4):479-87.






Página 2 de 41234